DAFTAR PUSTAKA
1. Frequently Asked Question FAQ075 Gynecologic Problem. The American College of Obstetricians and Gynecologists. July 2015
2. Grabosch SM, Karjane NW. Ovarian Cysts. January 2017. Available at:
http://emedicine.medscape.com/article/255865-overview
3. Kaloo PD et al. Management of Suspected Ovarian Masses in Premenopausal Women. Royal College of Obstetricians and Gynaecologists Green-top Guideline No. 62. November 2011.p1-14
4. Modesitt SC, Pavlik EJ, Ueland FR, et al. Risk of malignancy in unicolar ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol. 2003; 102:594-599
5. Dorum A, Blom GP, Ekerhovd E, et al. Prevalence and histologic diagnosis of adnexal cysts in postmenopausal women: an autopsy study. Am J Obstet Gynecol. 2005; 192:48-54
6. Myers ER, Bastian LA, Havrilesky LJ, et al. Management of adnexal mass. Evid Rep Technol Assess, 2006; 130:1-145
7. Knudsen UB, Tabor A, Mosgaard B, et al. Management of ovarian cysts. Acta Obstet Gynecol Scand. 2004;83:1012-1021
8. Royal College of Obstetricians and Gynecologists. Ovarian cysts in postmenopauseal women. October 2003. http://www.rcog.org.uk
9. National Cancer Institute. SEER cancer statistics review, 1975-2003. http://seer.cancer.gov
10. Grabosch SM, Karjane NW. Ovarian Cysts. Jan 2017. Available at:
http://emedicine.medscape.com/article/255865-overview
11. Kim KA, et al. Benign Ovarian Tumors with Solid and Cystic Components That Mimic Malignancy. American Journal of Roentgenology. 2004 182:5, 1259-1265
12. Hamed et al. Diagnostic Pathology 2013, 8:11. Available at :
http://www.diagnosticpathology.org/content/8/1/11
14. Zhu L et al. Overexpression of HE4 (human epididymis protein 4) enhances proliferation, invasion and metastasis of ovarian cancer.
Oncotarget, Vol. 7, No. 1. 2015. Available at:
www.impactjournals.com/oncotarget/
15. Jinping Li. HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. Int. J. Mol. Sci. 2013, 14, 6026-6043; doi:10.3390/ijms14036026
16. Zhuang H, Gao J, Hu Z, Liu J, Liu D, et al. (2013) Co-Expression of Lewis y Antigen with Human epididymis protein 4 in Ovarian Epithelial Carcinoma. PLoS ONE 8(7): e68994. doi:10.1371/journal.pone.0068994
17. Moore, R.G. et al. HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. Sci. Rep. 4, 3574 (2014).
18. Drapkin R. Human epididymis protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas. Cancer Res 2005; 65: (6). March 15, 2005
19. Mayo clinic staff. Ovarian cyst. Available at: www.mayoclinic.org
20. Nordqvist C. Ovarian Cysts: Causes, Symptoms and Treatments. 2015. Available at: http://www.medicalnewstoday.com
21. Suryati, Gambaran kejadian kista ovarium pada wanita usia Di rumah sakit khusus daerah ibu dan anak Pertiwi makassar tahun 2014, Universitas Indonesia Timur, Makassar, 2015
22. Safitri, Y., Pengalaman Wanita Usia Subur Dengan Kista Ovarium, Departemen Epidemiologi, Fakultas Kesehatan Masyarakat, Universitas Sumatera Utara, 2010.
23. Siringo D., Hiswani, Jemadi, Karakteristik penderita kista ovarium yang dirawat inap di Rumah Sakit St Elizabeth Medan tahun 2008-2012, Departemen Epidemiologi, Fakultas Kesehatan Masyarakat-Universitas Sumatera Utara, 2012.
24. Parazzini F, Moroni S, Negri E, La Vecchia C, Dal Pino D, Ricci E. Risk factors for functional ovarian cysts. Epidemiology. 1996 Sep;7(5):547-9.
25. Wiknjosastro, H. Tumor jinak pada alat genital, dalam Ilmu Kandungan, Yayasan Bina Pustaka Sarwono Prawirohardjo, Jakarta, 2005, Hal : 355-62
27. Choi, J.-H., Ovarian Epithelial Cancer: Etiology and Pathogenesis. BioWave, vol. 10. 2008
28. Llewellyn, dkk., Dasar-dasar Obstetri dan Ginekologi, Hipokrates, , Jakarta, 2001
29. Auersperg, N., Wong, A. S. T., Choi, K.-C., Kang, S. K. & Leung, P. C. K, Ovarian surface epithelium, in biology, endocrinology, and pathology. Endocrine Reviews, volume 22, 2001, page: 255-88.
30. Denny L et al. Staging classification and clinical practice guidelines for gynaecologic cancers. FIGO Committee on Gynecologic Oncology, 2009.
31. Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS collaborating group. J Clin Oncol.2007;25:3831-6
32. WHO, GLOBOCAN, International agency of research and cancer 2008
33. Bustam M., Epidemiologi Penyakit Tidak Menular, Penerbit Rineka Cipta, Jakarta, 2007.
34. du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol.2009;112:422-36.
35. Manuaba,I.B.C., & Manuaba, I.B.G., Buku Ajar Penuntun Kuliah Ginekologi, Penerbit CV. Trans Ino Media, Jakarta, 2010
36. William H., C..2007. American College of Obstetricians and Gynecologists Ovarian Cysts. http://emedicine.com diakses tanggal 24 Januari 2017
37. Robboy's, Pathology of The Female Reproductive Tract, Elsevier, 2009
38. Stanford JL. Oral contraceptives and neoplasia of the ovary.
Contraception. 1991 Jun;43(6):543-56.
40. Henderson,C., Kista Ovarium, dalam Buku Ajar Konsep Kebidanan, EGC, Jakarta, 2005
41. Rostgaard K. Does pregnancy induce the shedding of premalignat ovarian cells? Epidemiology.2003;14:168
42. Whittermore AS. Characteristic relating to ovarian cancer risk, Collaborating ovarian cancer group. Am J Epidemiol.1992;136:1184-1203
43. Kumar, V., Abbas, A.K., Fausto, N. & Aster, J.C., Robbins & Cotran, Ovarian Cyst, in Pathologic Basis of Diseases. 2010
44. Kurman RJ, Shih le-Ming. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008;27(2):151-60
45. Barber HR, Graber EA. The PMPO syndrome (postmenopausal palpable ovary syndrome). Obstet Gynecol 1971;38:921–3.
46. Kahraman K, Ozguven I, Gungor M, Atabekoglu CS. Extremely elevated serum CA-125 level as a result of unruptured unilateral endometrioma: the highest value reported. Fertil Steril 2007;88:15–7.
47. Van Calster B, Timmerman D, Bourne T, Testa AC, Van Holsbeke C, Domali E, et al. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst 2007;99:1706–14.
48. McLemore MR, Aouizerat BE, Lee KA, Chen LM, Cooper B, Tozzi M. A comparison of the cyclic variation in serum levels of CA-125 across the menstrual cycle using two commercial assays. Biol Res Nurs 2012;14:250–6.
49. Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel Ghaffar HM. Significance of HE4 estimation in comparison with CA-125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn Pathol 2013;23:8–11.
50. Demir RH, Marchand GJ. Adnexal masses suspected to Be benign treated with laparoscopy. JSLS 2012;16:71–84.
51. Timmerman D, Ameye L, Fischerova D, Epstein E,Melis GB, Guerriero S, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by
IOTA group. BMJ 2010;14(341):c6839.
52. Cramer DW, Bast Jr RC, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res 2011;4:365–74.
53. Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. Journal of clinical pathology. 2013;66(4):273-81.
54. Hussain, F. Gynecologic Tumor Markers Overview [Internet]. Medscape; 1 August 2012, cited 19 November 2014. Available at:
http://emedicine.medscape.com/article/269839-overview#showall.
55. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA-125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynecolo. 1990; 97:922-9
56. Granato T, Porpora MG, Longo F, Angeloni A, Manganaro L, Anastasi E. HE4 in the differential diagnosis of ovarian masses. Clinica Chimica Acta 446 (2015) 147–155
57. Vucetic Z. Risk of Ovarian Malignancy (ROMA) - Determining the Likelihood of Malignancy in Women with Pelvic Mass. European Medical Journal - Gynecology and Obstetrics, 2012:1:40-43
58. Terlikowska et al. Preoperative HE4, CA-125 and ROMA in the differential diagnosis of benign and malignant adnexal masses. Journal of Ovarian Research (2016) 9:43
59. Claudia Valentina Georgescu et al. Value of immunochemistry in confirming undifferentiated ovarian carcinomas. Morphol – Embryol. 2004. p.133–142
60. Kaspar HG, Crum CP. The Utility of Immunohistochemistry in the Differential Diagnosis of Gynecologic Disorders. Arch Pathol Lab Med. 2015;139:39–54
61. Chen VW, Ruiz B, Killeen JL, Cote´TR, Wu XC, Correa CN. Pathology and Classification of Ovarian Tumors North American Association of Central Cancer Registries. The American Cancer Society Cancer Supplement Volume 97 Number 10. 2003
63. Parmley, T, Benign Neoplasms of the Ovary, Fallopian Tube, and Parovarian Region. Glob. libr. women's med., 2008
64. Edelman GM: Topobiology. New York, Basic Books, 1988
65. Parmley TH: Embryology of the female genital canal. In Kurman RJ (ed): Blaustein's Pathology of the Female Genital Tract, 3rd ed. New York. Springer-Verlag, 1987
66. Karst AM, Drapkin R. Review Article Ovarian Cancer Pathogenesis: A Model in Evolution. Hindawi Publishing Corporation Journal of Oncology Volume 2010, Article ID 932371, 13 pages doi:10.1155/2010/932371
67. Nezhat FR, Apostol R, Nezhat C, Pejovic T. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. American Journal of Obstetrics & Gynecology. September 2015. p262-267
68. Kurman RJ, Shih LM. The Origin and Pathogenesis of Epithelial Ovarian Cancer- a Proposed Unifying Theory. Am J Surg Pathol. 2010 March ; 34(3): 433–443. doi:10.1097/PAS.0b013e3181cf3d79.
69. Montz FJ, Schlaerth JB, Morrow CP: The natural history of theca lutein cysts. Obstet Gynecol 72: 247, 1988
70. Forrester K, Almoguera C, Han K et al: Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 327: 298, 1987
71. Nogales F: Germ cell tumors of the ovary. In Fox H (ed): Haines and Taylor Obstetrical and Gynecological Pathology, p 637. New York, Churchill Livingstone, 1987
72. Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999;238:375–85.
73. Ono K, Tanaka T, Tsunoda T, et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 2000;60:5007–11.
74. Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 2001;98:1176–81.
76. Hough CD, Sherman-Baust CA, Pizer ES, et al. Largescale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000;60:6281–7.
77. Tapper J, Kettunen E, El-Rifai W, Seppala M, Andersson LC, Knuutila S. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet 2001;128:1–6.
78. Wang K, Gan L, Jeffery E, et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 1999;229:101–8.
79. Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J 2002;368:233–242.
80. Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene (2002) 21, p2768-73
81. Galgano MT et al. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Modern Pathology (2006) 19, 847–853
82. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 2006; 7: 167–74
83. Berry NB, Cho YM, Harrington MA, et al. Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter. Gynecologic Oncol 2004;92:896–904.
84. Devoogdt N, Revets H, Ghassabeh GH, et al. Secretory leukocyte protease inhibitor in cancer development
85. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695– 700.
86. Escudero JM. Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases. Clinical Chemistry 57:11. 1534–1544 (2011)
87. Molina R, Navarro J, Filella X, Castel T, Ballesta AM. S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol 2002;23:39–44.
89. Qureshi A, Pervez S. Allred scoring for ER reporting and its impact in clearly distinguishing ER negative from ER positive breast cancers. Journal Pakistan Medical Association, 60(5), (2010). p350-353
